DBV Technologies stock
Price history
−33.01% over the period1 year: from €2.47 (November 20, 2025) to €1.66 (November 20, 2026), −33.01%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €1.66 |
| October 30, 2026 | €1.70 |
| September 30, 2026 | €2.07 |
| August 31, 2026 | €2.37 |
| July 31, 2026 | €2.35 |
| June 30, 2026 | €2.82 |
| May 29, 2026 | €3.36 |
| April 30, 2026 | €3.63 |
| March 31, 2026 | €3.63 |
| February 27, 2026 | €3.59 |
| January 30, 2026 | €3.81 |
| December 31, 2025 | €3.38 |
| November 28, 2025 | €2.29 |
| November 20, 2025 | €2.47 |
At a glance
The company
Clinical-stage biopharmaceutical company developing epicutaneous immunotherapy products for food allergies and related conditions
Latest results
Quarter to September 30, 2026 · EPS -$0.03 (estimate -$0.02)
TickerLandia's take on DBV Technologies
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−63.16% from the 52-week high
Analysts · 4 analysts
Average target€3.60+117.13% vs. price
Buy 3 · Hold 0 · Sell 1 · Buy
TickerLandia Fingerprint: DBV Technologies
Compared with similar companies: very weak momentum, very low earnings stability, and very low growth.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh69
How much it costs relative to what it produces.
Metric Value Position in group Price/book 4.67 42 Price/sales 165.4 96 Profitabilitylow28
How much it earns on revenue and capital.
Metric Value Position in group Net margin 0.0% 31 Gross margin 100.0% 97 Operating marginabove 100%: likely one-off items −5,577.0% 4 ROE −205.9% 6 ROA −79.9% 2 Earnings stabilityvery low14
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 916.2% 16 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthvery low20
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +5.18% 15 Revenue growth (year over year) −42.90% 9 Earnings growth (year over year) −41.07% 35 Financial strengthaverage55
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.05 63 Current ratio 3.24 47 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak3
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) −47.51% 2 1-year return −33.01% 6 Distance from 200-day average −40.20% 1 Relative strength (3 months) −29.12% 4 Riskhigh69
How much the price swings.
Metric Value Position in group Beta (1 year) 0.32 13 Volatility (60 days) 63.2% 96 Maximum drawdown (12 months) 63.2% 98
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
DBV Technologies is cheaper than similar companies
DBV Technologies's Price/book: 3.94, −12% against the median of a group of 10 similar companies (4.45).
Compared with 11 similar companies
| Metric | DBV Technologies | Position in the group | Band |
|---|---|---|---|
| Operating margin | -5,577.0% | Low | |
| ROE | -205.9% | Low | |
| Debt/equity | 0.05 | Middle | |
| Price/book | 3.94 | Middle | |
| Net margin | 0.0% | Middle |
Grey band: the middle half of the group; tick: the median; dot: DBV Technologies. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.6M
Latest quarter · Q3 2026
Net income
-$64.5M
Latest quarter · Q3 2026
Quarterly net margin
-4,031.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €520.95M
- EPS
- -€0.52
- Volume
- 1.04M
- Daily trading
- €2.33M
- Dividend yield
- 0.00%
How DBV Technologies is changing
All resultsRevenue fell 13.0% a year on average over the last 5 years
Operating margin fell from −1,994.9% to −2,609.2%
Shares outstanding up 158.0% in 5 years
Returns
DBV Technologies returns
€1,000 invested in DBV Technologies 5 years ago, on November 22, 2021, would be worth €312 today: −68.82% in total, −20.82% per year. This is the price return only: dividends are excluded.
| Period | DBV Technologies | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | −3.10% | +1.14% | €969 |
| 6 months | −48.73% | −2.34% | €513 |
| Year to date | −50.95% | −2.72% | €491 |
| 1 year | −33.01% | −0.67% | €670 |
| 3 years | +1.10% | +9.39% | €1,011 |
| 5 years | −68.82% | +11.58% | €312 |
| 10 years | −97.56% | +75.02% | €24 |
Over the last 6 months it has done better than 0% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
DBV Technologies: technical analysis
DBV Technologies is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 98.0% below its all-time closing high (€83.51, October 12, 2017).
- Trend
- Downward
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- −40.20%
Support and resistance
Price areas where DBV Technologies has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€2.63+58.38%2 touches, last on August 19, 2026
- Resistance€2.53+52.29%2 touches, last on June 30, 2026
- Resistance€2.22+33.84%3 touches, last on November 11, 2026
- Last price€1.66
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved little with the CAC 40.
- Beta (1 year) vs CAC 40
- 0.32
- Volatility (60 sessions, annualised)
- 63.2%
- Largest fall in the last year
- −63.24%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
DBV Technologies: seasonality
Average monthly price change over 15 years
Over the last 15 years, the strongest month for DBV Technologies has been April: +7.01% on average, positive in 8 years out of 15. The weakest has been October: −6.63% on average, positive in 4 years out of 15. November, the current month, has been positive in 7 years out of 14 (−0.24% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +6.69% | −4.25% | 5 of 14 |
| February | +0.97% | −1.50% | 6 of 14 |
| March | +4.01% | +4.54% | 9 of 14 |
| April | +7.01% | +0.14% | 8 of 15 |
| May | −1.96% | −5.91% | 6 of 15 |
| June | +0.75% | −0.96% | 6 of 15 |
| July | +4.48% | +2.52% | 8 of 15 |
| August | −2.55% | −1.85% | 7 of 15 |
| September | −1.10% | −5.59% | 5 of 15 |
| October | −6.63% | −12.61% | 4 of 15 |
| November | −0.24% | −0.93% | 7 of 14 |
| December | +3.81% | +6.33% | 9 of 14 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
DBV Technologies and its competitors
Viaskin Peanut, an epicutaneous immunotherapy product for peanut allergy, has completed a Phase 3 clinical trial, while Viaskin Milk, aimed at cow's milk protein allergy and eosinophilic esophagitis, is in Phase 1/2 trials. The company also runs earlier-stage research into celiac disease and develops the Viaskin technology platform, which is designed to potentially treat food allergy. Its collaboration with Nestlé Health Science covers MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers.
- Headquarters
- Châtillon, France
- Employees
- 179
- Founded
- 2002
- Chief executive
- Daniel Tassé
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DBV TechnologiesDBV | $572.52M | -5,577.0% | — | −48.73% |
| GubraGUBRA | $730.02M | -73.1% | — | −22.24% |
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
Same industry or related industries, similar size. Compare DBV Technologies with its competitors · Full profile
